Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the , being held October 3-7, 2023 in Charleston, SC.

Oral Presentation:

Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Oral #O21)

• Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
• Date and time: Saturday, October 7, 7:45-8:45 a.m. E.T.
• Location: PAC, Charleston Area Convention Center
  
  

Poster Sessions:

Abstract Title: Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (Poster #P371)

• Presenter: Kristl G. Claeys, MD, PhD, University Hospitals Leuven, Leuven, Belgium
• Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
• Location: Ballroom A-C, Charleston Area Convention Center
  
  

Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #P373)

• Presenter: Jordi Díaz-Manera, MD, PhD, John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, U.K.
• Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
• Location: Ballroom A-C, Charleston Area Convention Center
  
  

Abstract Title: Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #P372)

• Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.
• Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
• Location: Ballroom A-C, Charleston Area Convention Center
  
  

Abstract Title: Disease burden, treatment patterns and healthcare resource utilization associated with Pompe disease in Sweden: a real-world evidence study (ePoster #VP369)

• Presenter: Christopher Lindberg, MD, Neuromuscular Centre, Sahlgrenska University Hospital, Gothenburg, Sweden
• Poster Session 3: Friday, October 6, 2:00-3:00 p.m. E.T.
• Location: Virtual Platform
  
  

For more information on the World Muscle Society 2023, please visit .

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at , and follow on and .

CONTACTS:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations

(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Communications

(609) 662-5079

FOLD–G